News|Articles|June 5, 2026

Radiation Oncology Trials You May Have Missed at ASCO 2026

Fact checked by: Roman Fabbricatore, Justin Mancini

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought forward a wave of practice-changing data, with radiation oncology taking center stage in several pivotal discussions. From innovative, localized delivery systems to optimized chemoradiotherapy regimens, the presentations highlighted a strong push toward maximizing therapeutic efficacy while preserving patient quality of life.

Related to this article

October 19th, 2026

Neoadjuvant Radiotherapy Challenges the Surgery-First Paradigm in Breast Cancer

Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.

October 18th, 2026

TARGIT-B IORT Boost Blunts Distant Relapse in Young Patients With Breast Cancer

Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.

October 17th, 2026

Radiation Omission in Favorable Breast Cancer Hinges on Endocrine Adherence

Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.

Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.

October 16th, 2026

Addressing Prospective Data Gaps for Radiotherapy Use in Multiple Myeloma

Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.

There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.

October 16th, 2026

Using Radiotherapy Strategically Alongside CAR T, Bispecifics in Myeloma

There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.

October 15th, 2026

Proton Therapy Tied to Less Hypothyroidism After Supraclavicular Breast RT

Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.

Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.

October 14th, 2026

What Data Should Radiation Oncologists Know From ASTRO 2026?

Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.

October 9th, 2026

Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.